ArticleMucosal immunology2018
The increased protection and pathology in Mycobacterium tuberculosis-infected IL-27R-alpha-deficient mice is supported by IL-17A and is associated with the IL-17A-induced expansion of multifunctional T cells.
Article in Mucosal immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Context-specific roles for IL-17 in tuberculosis.PLoS pathogens · 2026Review
- Immunopathogenesis of tuberculosis: cellular mechanisms and immune modulation.Veterinary research · 2025Review
- IL-27 signaling limits the diversity of antigen-specific T cells and interferes with protection induced by BCG vaccination.Tuberculosis (Edinburgh, Scotland) · 2025Article
- IL-27 attenuated macrophage injury and inflammation induced by Mycobacterium tuberculosis by activating autophagy.In vitro cellular & developmental biology. Animal · 2025Article
- Sex-specific impact of B cell-derived IL-10 on tuberculosis resistance.Frontiers in immunology · 2025Article
- Novel target and cofactor repertoire for the transcriptional regulator JTY_0672 fromFrontiers in microbiology · 2024Article
- IL-27 alters inflammatory cytokine expression and limits protective immunity againstFrontiers in immunology · 2024Article
- Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus.Frontiers in immunology · 2023Review
- High-DoseCells · 2022Article
- Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis.Cellular & molecular immunology · 2021Article
- Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease.Science translational medicine · 2021Article
- Interleukin-27 in Tuberculosis: A Sheep in Wolf's Clothing?Frontiers in immunology · 2021Review
- Article
- The Role of gp130 Cytokines in Tuberculosis.Cells · 2020Review
- Loss of IL-27Rα Results in Enhanced Tubulointerstitial Fibrosis Associated with Elevated Th17 Responses.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Article
- Regional Dichotomy in Enteric Mucosal Immune Responses to a PersistentFrontiers in immunology · 2020Article
- PI3-Kinase δγ Catalytic Isoforms Regulate the Th-17 Response in Tuberculosis.Frontiers in immunology · 2019Review
- Cell Differentiation Degree as a Factor Determining the Role for Different T-Helper Populations in Tuberculosis Protection.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During Mycobacterium tuberculosis (Mtb) infection, mice lacking the IL-27R exhibit lower bacterial burdens but develop an immunopathological sequelae in comparison to wild-type mice. We here show that this phenotype correlates with an enhanced recruitment of antigen-specific CCR6
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.